1. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome 
H.C Fung, A Stein, M.L Slovak, M.R O’Donnell, D.S Snyder, S Cohen, D Smith, A Krishnan, R Spielberger, R Bhatia, S Bhatia, P Falk, A Molina, A Nademanee, P Parker, R Rodriguez, J Rosenthal, R Sweetman, N Kogut, F Sahebi, L Popplewell, N Vora, G Somlo, K Margolin, W Chow, E Smith, S.J Forman 
Biology of Blood and Marrow Transplantation 
Volume 9, Issue 12, Pages (December 2003)
DOI: /j.bbmt

2. Figure 1 Overall and disease-free survival (n = 68).
Biology of Blood and Marrow Transplantation 2003 9, DOI: ( /j.bbmt )

3. Figure 2
Time to relapse for all 68 patients with primary refractory AML.
Biology of Blood and Marrow Transplantation 2003 9, DOI: ( /j.bbmt )

4. Figure 3
Kaplan-Meier disease-free survival for patients with intermediate and unfavorable cytogenetics.
Biology of Blood and Marrow Transplantation 2003 9, DOI: ( /j.bbmt )

5. Figure 4
Kaplan-Meier time to relapse for patients with intermediate and unfavorable cytogenetics.
Biology of Blood and Marrow Transplantation 2003 9, DOI: ( /j.bbmt )

6. Figure 5
Disease-free survival for patients with related donors versus unrelated donors. MRD indicates matched related donor; MUD, matched unrelated donor.
Biology of Blood and Marrow Transplantation 2003 9, DOI: ( /j.bbmt )